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Recent advances in achieving highly durable clinical
responses via inhibition of immune checkpoint molecules
have revolutionized the outlook for cancer immun-
otherapy. However, such responses are only observed in a
minority of patients, suggesting that strategies to further
augment antitumor immune activity may provide addi-
tional clinical benefit. ALT-803 is an IL-15 superagonist:
IL-15Ra-Fc complex capable of stimulating T cell and NK
cell responses without inducing Treg activity. ALT-803
has improved pharmacokinetics and biodistribution com-
pared to native IL-15, allowing this complex to exhibit
more potent efficacy than IL-15 in various hematologic
and solid tumor models. Mechanism-of-action studies
showed that ALT-803 is capable of inducing both innate
effector-like and adaptive T cell antitumor activity, sug-
gesting that the immunostimulatory effects of ALT-803
could compliment the activity of checkpoint inhibitors to
block tumor immune evasion. To assess this, we utilized a
murine 5T33P myeloma model in which ALT-803 was
shown to be effective at decreasing tumor burden in the
bone marrow and prolonging animal survival. Treatment
of mice bearing established 5T33P tumors (5/group) with
5 mg/kg anti-PD-L1 mAb also prolonged survival com-
pared to controls (P > 0.01), whereas treatment with 1.25
mg/kg anti-PD-L1 mAb or 10 mg/kg anti-CTLA-4 mAb
had no significant antitumor effect (p < 0.05). Consistent
with these results, 5T33P cells were found to express
PD-L1 but not CD80/CD86. Treatment with sub-optimal
0.25 mg/kg anti-PD-L1 mAb or 50 µg/kg ALT-803 was
ineffective at prolonging survival of 5T33P-bearing mice
(median survival; PBS, 27 days; anti-PD-L1 mAb, 31 day;
ALT-803, 28 days). However, combination therapy with
sub-optimal anti-PD-L1 mAb plus ALT-803 extended
median survival to 66 days (p < 0.05 vs. controls). These
combination therapies were also evaluated in a metastatic
murine CT26 colon carcinoma model that was previous
used to show increased efficacy of IL-15+anti-PD-L1+anti-
CTLA-4 mAb treatment. Notably, ALT-803+anti-PD-L1
+anti-CTLA-4 mAb treatment provided greater survival
benefit to mice with metastatic CT26 tumors than treat-
ment with vehicle or ALT-803 alone (median survival:
combined therapy, 53 days vs. PBS, 15 days; vs. ALT-803,
22.5 days; both p < 0.01) or the IL-15+anti-PD-L1+anti-
CTLA-4 mAb combination (median survival: 18 days;
p < 0.001). In all of these models, combination therapies
of ALT-803 and anti-checkpoint Abs were well tolerated.
Characterization of immune cell activity responsible for
improved antitumor efficacy is underway. Overall, these
results confirm that enhanced antitumor responses can be
achieved by combining immune checkpoint blockers with
ALT-803, warranting evaluation of these strategies in the
clinical setting.
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